Predictive Oncology (NASDAQ:POAI) Shares Pass Below Two Hundred Day Moving Average – Should You Sell?

Predictive Oncology Inc. (NASDAQ:POAI) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $13.09 and traded as low as $5.95. Predictive Oncology shares last traded at $6.55, with a volume of 19,470 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Predictive Oncology in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce”.

Predictive Oncology Stock Performance

The company has a market capitalization of $27.58 million, a PE ratio of -0.32 and a beta of 1.26. The firm has a fifty day simple moving average of $12.19 and a 200 day simple moving average of $13.09.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings results on Wednesday, August 13th. The medical instruments supplier reported ($3.30) EPS for the quarter, missing the consensus estimate of ($1.35) by ($1.95). Predictive Oncology had a negative net margin of 587.31% and a negative return on equity of 722.01%. The firm had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $1.50 million. Research analysts expect that Predictive Oncology Inc. will post -2.08 EPS for the current fiscal year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.